Discovery of Novel Pterostilbene-Based Derivatives as Potent and Orally Active NLRP3 Inflammasome Inhibitors with Inflammatory Activity for Colitis
Authors:
- 10 September 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (18) , 13633-13657
Abstract
Studies have shown that the abnormal activation of the NLRP3 inflammasome is involved in a variety of inflammatory-based diseases. In this study, a high content screening model targeting the activation of inflammasome was first established and pterostilbene was discovered as the active scaffold. Based on this finding, total of 50 pterostilbene derivatives were then designed and synthesized. Among them, compound 47 was found to be the best one for inhibiting cell pyroptosis [inhibitory rate (IR) = 73.09% at 10 μM], showing low toxicity and high efficiency [against interleukin-1β (IL-1β): half-maximal inhibitory concentration (IC50) = 0.56 μM]. Further studies showed that compound 47 affected the assembly of the NLRP3 inflammasomes by targeting NLRP3. The in vivo biological activity showed that this compound significantly alleviated dextran sodium sulfate (DSS)-induced colitis in mice. In general, our study provided a novel lead compound directly targeting the NLRP3 protein, which is worthy of further research and structural optimization.Keywords
Funding Information
- National Natural Science Foundation of China (21977001)
- Scientific Research Foundation for Advanced Talents, Hefei University (20RC50)
This publication has 66 references indexed in Scilit:
- Mitochondrial Cardiolipin Is Required for Nlrp3 Inflammasome ActivationImmunity, 2013
- Caspase‐1‐induced pyroptotic cell deathImmunological Reviews, 2011
- Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1βProceedings of the National Academy of Sciences, 2010
- Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasomeGut, 2010
- Sterile inflammatory responses mediated by the NLRP3 inflammasomeEuropean Journal of Immunology, 2010
- Anti-inflammatory Compounds Parthenolide and Bay 11-7082 Are Direct Inhibitors of the InflammasomeJournal of Biological Chemistry, 2010
- Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 ExpressionThe Journal of Immunology, 2009
- The Inflammasomes: Guardians of the BodyAnnual Review of Immunology, 2009
- The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesisNature Immunology, 2009
- Interleukin-4 hyporesponsiveness in inflammatory bowel disease: Immune defect or physiological response?Gastroenterology, 1995